Early PFT Monitoring Post-allo-HSCT Crucial for AFO Detection and BOS Prevention
The following is a summary of “Clinical impact of airflow obstruction after allogeneic...
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 1 - 20 of 274 results for 'HSCT'
AHSCT Effective and Safe for Pediatric Patients With Treatment-Refractory Autoimmune Diseases
To evaluate the long-term effectiveness and safety of autologous hematopoiesis stem cell...
Read More
Allogeneic HSCT for Myelofibrosis: What to Know as More Patients Receive Treatment
Authors of a recent review provide updates on stem cell transplants for myelofibrosis, with an emphasis on managing graft versus host disease and relapse.
Read More
Genomic data optimizes hematopoietic stem-cell transplantation (HSCT) timing for myelodysplastic syndromes (MDS) and improves patient outcomes
1. A decision support system using the Molecular International Prognostic Scoring System (IPSS-M)...
Read More
Allo-HSCT in Intermediate-Risk AML: Is It Needed?
An evaluation of allo-HSCT as a treatment for intermediate-risk acute myeloid leukemia and if allogeneic transplantation is necessary.
Read More
Impact in Normalization of CSF mtDNA Levels Post aHSCT in MS
The following is a summary of “Cerebrospinal fluid mtDNA concentrations are increased in multiple...
Read More
HSCT Post-Myeloablation Leads to Longterm Normalization of SSc Molecular Signatures
The following is a summary of “Myeloablation followed by hematopoietic stem cell transplantation...
Read More
Post-Mogamulizumab Allo-HSCT in Patients with T-Cell Lymphoma
The following is a summary of “Allogeneic hematopoietic stem cell transplantation after...
Read More
Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
WEDNESDAY, Feb. 21, 2024 (HealthDay News) — Patients with therapy-related myelodysplastic...
Read MoreAdvertisement
Significance of Bone Marrow NCC in Acute Lymphoblastic Leukemia Post allo-HSCT
The following is a summary of “Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation,” published in the...
Read More
Optimizing Reduced Intensity Conditioning for Allo-HSCT: A Comparative Analysis of FluMel and FluTreo
The following is a summary of “Fludarabine melphalan versus fludarabine treosulfan for reduced...
Read More
Third COVID-19 mRNA Vaccine Dose Boosts Antibodies in Allogeneic HSCT Recipients
The following is a summary of “Antibody response after third dose of COVID-19 mRNA vaccination in...
Read MoreEffectiveness of Venetoclax Plus Decitabine Conditioning Regimen for Allogeneic HSCT in High-Risk Myeloid Neoplasms Patients
The following is a summary of “Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms,” published in...
Read More
aHSCT Beneficial for Most Patients With Relapsing-Remitting MS
TUESDAY, Sept. 26, 2023 (HealthDay News) — Autologous hematopoietic stem cell...
Read More
Distress and QoL Screening in Pediatric Patients Following Allogeneic or Autologous HSCT Using Self-Reporting, Biomarkers, and PO-Bado Scale
The following is a summary of “Screening for distress and quality of life in pediatric patients...
Read More
Spleen Volume Linked to Outcome After HSCT for Leukemia Patients
WEDNESDAY, July 19, 2023 (HealthDay News) — For patients with acute myeloid leukemia (AML),...
Read More
Experimental Prophylaxis Beneficial for Patients Undergoing HSCT
FRIDAY, June 23, 2023 (HealthDay News) — For patients with hematologic cancer undergoing...
Read MoreImmune-mediated cytopenias (IMCs) after HSCT for pediatric non-malignant disorders: epidemiology, risk factors, pathogenesis, and treatment.
Hematopoietic stem cell transplantation (HSCT) represents a curative option for pediatric patients affected by malignant and non-malignant disorders. Several complications may arise during the post-transplantation period,...
Read MoreHigh-Risk Hodgkin Lymphoma and BV+Nivolumab After HSCT
The following is a summary of “Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial”...
Read More
In-Hospital and Post-Transplant Risk Factors in ARDS After HSCT
The following is the summary of “Post-Transplant and In-Hospital Risk Factors for ARDS After...
Read More